Anlotinib for Esophageal Cancer (AFEC)
A Real World Study on the Effect of Single or Combined Treatment of Anlotinib on Survival and Prognosis of Advanced Esophageal Cancer
1 other identifier
observational
200
1 country
1
Brief Summary
The purpose of this study is to observe and explore the effect of single or combined treatment of arotinib on the survival and prognosis of patients with advanced esophageal cancer in the real world, and to summarize the treatment experience of a wide range of people.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2021
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 8, 2021
CompletedStudy Start
First participant enrolled
July 15, 2021
CompletedFirst Posted
Study publicly available on registry
July 19, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 15, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
July 15, 2024
CompletedJuly 19, 2021
July 1, 2021
2 years
July 8, 2021
July 8, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
OS
Overall Survival
From date of admission until the date of death from any cause, assessed up to 24 months
Secondary Outcomes (1)
PFS
From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Interventions
This is an observational study
Eligibility Criteria
Patients with advanced esophageal cancer
You may qualify if:
- Age: ≥ 18 years old, male or female;
- Patients with esophageal cancer were diagnosed;
- Patients assessed by doctors to benefit from single or combined treatment of arotinib;
- Patients volunteered to join the project.
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Anyang Cancer Hospital
Anyang, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chief physician
Study Record Dates
First Submitted
July 8, 2021
First Posted
July 19, 2021
Study Start
July 15, 2021
Primary Completion
July 15, 2023
Study Completion
July 15, 2024
Last Updated
July 19, 2021
Record last verified: 2021-07
Data Sharing
- IPD Sharing
- Will not share